Congress, FTC, consumers demand answers on EpiPen’s price hike
Analysts say ‘savvy branding’ drove the anti-allergy injector’s popularity. Federal lawmakers—and parents facing back-to-school expenses—call the steep increase ‘outrageous.’
Enough is enough, say several senior members of Congress, the Federal Trade Commission, members of the health care community and parents.
Even disgraced former Turing Pharmaceuticals CEO Martin Shkreli, himself accused of price gouging on medication to treat HIV, is calling Mylan “vultures.” Shkreli posed a rhetorical question on NBCNews.com: “What drives this company’s moral compass?”
Bloomberg reported Tuesday that members of Congress are demanding answers:
Become a Ragan Insider member to read this article and all other archived content.
Sign up today
Already a member? Log in here.
Learn more about Ragan Insider.
